Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs CGON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

CGON Overall Winner 6-Pillar Tally: CVM 2 – 3 CGON (1 Tie) Matrix Metrics: CVM 4 – 5 CGON

As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CGON carries 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. 0.0% operating margin) and revenue trajectory (-3.7% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 53.1); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs CGON
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.1 · SMA20: $1.46 · SMA50: $1.66
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.75β · 89% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25

6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 CGON)

Columns: Metric · CVM · CGON
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale CGON
Revenue Growth (YoY) -62.7% -3.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 $6.2M
Market Cap $20.9M $6.3B
3. Profitability & Quality CVM
Gross Margin N/A N/A
Operating Margin 0.0% -4293.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -28.3%
4. Balance Sheet & Cash Flow CGON
Cash Generation (TTM) -$17M -$189M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 238.6% (85th %ile)
Put/Call OI Skew N/A 0.35x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (4) vs CGON (5)
Institutional Metric CVM CGON Criterion Row Edge
Market Capitalization
Scale
$20.9M $6.3B Larger Scale CGON
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% -3.7% Higher Growth CGON
Operating Margin (TTM)
Profitability
0.0% -4293.5% Higher Margin CVM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -28.3% Higher ROE CGON
52-Week Range Position
Momentum
10% ($1–$8) 84% ($37–$94) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 0.75β · 89% Vol Lower Realized Risk CGON
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $6.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$189M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +53.1 pp
CVM: -11.17% · CGON: +41.93%
3M Horizon CGON +11.34 pp
CVM: +0.0% · CGON: +11.34%
6M Horizon CGON +42.54 pp
CVM: -7.56% · CGON: +34.98%
1Y Horizon CGON +183.11 pp
CVM: -75.98% · CGON: +107.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue CGON Revenue CVM Op. Margin CGON Op. Margin Margin Leader
FY2011 $0M N/A -1881.0% N/A CVM
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2023 N/A $0M N/A -27180.9% CGON
FY2024 N/A $0M N/A -10067.3% CGON
FY2025 N/A $0M N/A -4722.1% CGON

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs CGON Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CGON carries 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. 0.0% operating margin) and revenue trajectory (-3.7% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 53.1); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGON leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). Across the 7-period historical trajectory (FY2011 to FY2025), CVM cumulative revenue shifted N/A while CGON shifted N/A. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus CGON (-28.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.